Tek antagonists
AssigneeImmunex Corporation
InventorsDouglas P. Cerretti, Luis G. Borges, William C. Fanslow, III
Life of this patent
Estimating the term…
Abstract
The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.
Claims17
A method of inhibiting angiogenesis in a mammal in need of such treatment, comprising administering to the mammal an inhibition-effective amount of a polypeptide comprising a fragment of Tek extracellular domain, shown as residues 19–745 of SEQ ID NO:1, wherein the polypeptide lacks residues 473–745 of SEQ ID NO:1 containing fibronectin type III (FN III) motifs and wherein the polypeptide has a higher binding affinity for angiopoietin-1 or angiopoietin-2 or angiopoietin-4 than does a polypeptide comprising the full length Tek extracellular domain.
A method of inhibiting angiogenesis in a mammal in need of such treatment, comprising administering to the mammal an inhibition-effective amount of a compound selected from the group consisting of:
- (a) a polypeptide comprising a fragment of Tek extracellular domain, shown as residues 19–745 of SEQ ID NO:1, wherein the polypeptide lacks residues 473–745 of SEQ ID NO:1 containing fibronectin type III (FN III) motifs and wherein the polypeptide has a higher binding affinity for angiopoietin-1 or angiopoietin-2 or angiopoietin-4 than does a polypeptide comprising the full length Tek extracellular domain;
- and
- (b) a multimer of the polypeptide described in (a).
A method of inhibiting the binding of a Tek ligand to Tek in a mammal in need of such treatment, comprising administering to the mammal an inhibition-effective amount of compound selected from the group consisting of:
- (a) a polypeptide comprising a fragment of Tek extracellular domain, shown as residues 19–745 of SEQ ID NO:1, wherein the polypeptide lacks residues 473–745 of SEQ ID NO:1 containing fibronectin type III (FN III) motifs and wherein the polypeptide has a higher binding affinity for angiopoietin-1 or angiopoietin-2 or angiopoietin-4 than does a polypeptide comprising the full length Tek extracellular domain;
- and
- (b) a multimer of the polypeptide described in (a).
Dependencies are inferred from the claim text.